1. Youd E, Moore L. COVID-19 autopsy in people who died in community settings: the first series. J Clin Pathol 2020;73:840–844.

2. Mall AS. Analysis of mucins: role in laboratory diagnosis. J Clin Pathol 2008;61:1018–1024.

3. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68–73.

4. Hu C, Wu C, Yang E, et al. Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. Clin Rheumatol 2019;38:2181–2187.

5. Scarpati G, Baldassarre D, Boffardi M, et al. Krebs von den Lungen 6 (KL-6) levels in COVID-19 ICU patients are associated with mortality. J Anesth Analg Crit Care 2022;2:37.

6. Maruyama S, Nakamori Y, Nakano H, et al. Peak value of serum KL-6 may be useful for predicting poor prognosis of severe COVID-19 patients. Eur J Med Res 2022;27:69.

7. Karadeniz H, Avanoğlu Güler A, Özger HS, et al. The prognostic value of lung injury and fibrosis markers, KL-6, TGF-β1, FGF-2 in COVID-19 patients. Biomark Insights 2022;17:11772719221135443.

8. d’Alessandro M, Bergantini L, Cameli P, et al. Serial KL-6 measurements in COVID-19 patients. Intern Emerg Med 2021;16:1541–1545.

9. Scotto R, Pinchera B, Perna F, et al. Serum KL-6 could represent a reliable indicator of unfavourable outcome in patients with COVID-19 pneumonia. Int J Environ Res Public Health 2021;18:2078.

10. Park M, Hur M, Kim H, Lee CH, Lee JH, Nam M. Usefulness of KL-6 for predicting clinical outcomes in hospitalized COVID-19 patients. Medicina (Kaunas) 2022;58:1317.

11. Jeong SJ, An M, Jang M, et al. Severity of COVID-19 associated with SARS-CoV-2 variants dominant period in the Republic of Korea. Public Health Weekly Report 2023;16:1464–1487.

12. Zheng P, Liu X, Huang H, et al. Diagnostic value of KL-6 in idiopathic interstitial pneumonia. J Thorac Dis 2018;10:4724–4732.

13. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006;11:164–168.

14. Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med 2014;108:1031–1039.

15. Yokoyama A, Kohno N, Kondo K, et al. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia. Respirology 1998;3:199–202.

16. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995;108:311–315.

17. Wakamatsu K, Nagata N, Kumazoe H, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig 2017;55:16–23.

18. Patra T, Meyer K, Geerling L, et al. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog 2020;16:e1009128.

19. Kostopanagiotou K, Schuurmans MM, Inci I, Hage R. COVID-19-related end stage lung disease: two distinct phenotypes. Ann Med 2022;54:588–590.

20. Vianello A, Guarnieri G, Braccioni F, et al. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med 2021;60:307–316.

21. Piazza O, Scarpati G, Boccia G, Boffardi M, Pagliano P. KL-6 in ARDS and COVID-19 patients. Transl Med UniSa 2022;24:12–15.

22. Matuszewski M, Szarpak L, Rafique Z, et al. Prediction value of KREBS von den Lungen-6 (KL-6) biomarker in COVID-19 patients: a systematic review and meta-analysis. J Clin Med 2022;11:6600.

23. Azekawa S, Chubachi S, Asakura T, et al. Serum KL-6 levels predict clinical outcomes and are associated with MUC1 polymorphism in Japanese patients with COVID-19. BMJ Open Respir Res 2023;10:e001625.

24. Deng K, Fan Q, Yang Y, et al. Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: a longitudinal retrospective analysis. J Med Virol 2021;93:2505–2512.